SMO and medulloblastoma: Arsenic trioxide, which targets GLI2 for degradation, inhibits the growth of Vismodegib-resistant medulloblastoma in vivo, and the combination of arsenic trioxide and itraconazole, a SMO inhibitor, shows greater anti-tumor efficacy in vivo than either agent alone [28].